Blue Cross Of Massachusetts Will Not Cover Controversial Alzheimer’s Drug

Blue Cross said it reviewed clinical studies and talked to specialists before concluding that Aduhelm, priced at $56,000 a year, is“ investigational,” or unproven. Blue Cross, which has 2.8 million members, joins Point32Health, the state’ s second-biggest insurer, in deciding not to include the drug in its coverage. Several Blue Cross plans in other states have also…